On Apr. 16, 2020, Soligenix announced it has executed an agreement for the exclusive worldwide license of CoVaccine HTﾙ, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp., for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu.

CoVaccine HT is a novel adjuvant, which has been shown to enhance both cell-mediated and antibody-mediated immunity.